MA16.08 Impact of Site of CAN-2409 Injection Plus Continued Immune Checkpoint Inhibitor (ICI) In CI-resistant stage III/IV NSCLC

Authors: Sterman, D., Aggarwal, C., Alesi, E.R., Maldonado, F., Mehra, R., Bestvina, C., Reisenauer, J.S., Swartz, L.K., Puri, S., Ibrahim, O., Eapen, G., Duault, C., Del Valle, D.M., Kim-Schulze, S., Gonzalez-Kozlova, E., Gnjatic, S., Manzanera, A., Lopez, L., Dwyer, J., Rao, S., Nichols, G., Barone, F., Tak, P.P.

Source: In Journal of Thoracic Oncology October 2024 19(10) Supplement:S123-S123